cPLA2–Inhibitor (stoPLA) – New compounds for the topical treatment of skin inflammation
Novel group of nonsteroidal anti-inflammatory drugs: The new class of heteroaryl-substituted acetone derivatives inhibits effectively the cytosolic phospholipase A2 (cPLA2).
The compounds interact with the synthesis of prosta-glandins and leukotrienes and reduce inflammatory processes. The substances have an excellent solubility profile. The heteroaryl-substituted acetone derivatives provide the platform for the development of new pharmaceutical products for the treatment of inflammatory diseases of the skin, such as psoriasis and atopic dermatitis.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Making diamonds at ambient pressure
Scientists develop novel liquid metal alloy system to synthesize diamond under moderate conditions. Did you know that 99% of synthetic diamonds are currently produced using high-pressure and high-temperature (HPHT) methods?[2]…
Eruption of mega-magnetic star lights up nearby galaxy
Thanks to ESA satellites, an international team including UNIGE researchers has detected a giant eruption coming from a magnetar, an extremely magnetic neutron star. While ESA’s satellite INTEGRAL was observing…
Solving the riddle of the sphingolipids in coronary artery disease
Weill Cornell Medicine investigators have uncovered a way to unleash in blood vessels the protective effects of a type of fat-related molecule known as a sphingolipid, suggesting a promising new…